Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...
The following slide deck was published by Calithera Biosciences, Inc. in conjunction with this Read more ...
-Results from ENTRATA Phase 2 trial of telaglenastat in patients with advanced renal cell carcinoma (RCC) accepted as Late Breaking Oral Presentation- -Data from INCB001158 clinical program accepted as Oral Presentation- SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -...
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...
Calithera Biosciences, Inc. (CALA) Q2 2019 Earnings Conference Call August 08, 2019, 17:00 ET Company Participants Jennifer McNealey - VP, IR & Strategy Susan Molineaux - Co-Founder, CEO, President & Director Keith Orford - Chief Medical Officer Stephanie Wong - SVP, Fi...
Calithera Biosciences (NASDAQ: CALA ): Q2 GAAP EPS of -$0.58 beats by $0.07 . More news on: Calithera Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 8, 2019-- SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and develop...
I think resentment is when you take the poison and wait for the other person to die " - M.T., A Sponsorship Guide for 12-Step Programs Today, we take a look at a 'Busted IPO' from the biotech sector. The company's pipeline continues to slowly advance, and the stock has seen some insider b...
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today anno...
"The merit of all things lies in their difficulty." - Alexandre Dumas, The Three Musketeers We have kicked off the second half of 2019 with the S&P 500 at all-time highs after rallying some 17% so far this year. That is the best first half of performance for the index since 1997. One...
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
OTCMKTS Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...